Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
Geok Choo Sim, Natalia Martín‐Orozco, Lei Jin, et al.
Journal of Clinical Investigation (2013) Vol. 124, Iss. 1, pp. 99-110
Open Access | Times Cited: 210

Showing 1-25 of 210 citing articles:

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
Nathalie Chaput, Patricia Lepage, Clélia Coutzac, et al.
Annals of Oncology (2017) Vol. 28, Iss. 6, pp. 1368-1379
Open Access | Times Cited: 1084
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
Priti S. Hegde, Vaios Karanikas, Stefan Evers
Clinical Cancer Research (2016) Vol. 22, Iss. 8, pp. 1865-1874
Open Access | Times Cited: 792
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
Silvia C. Formenti, Nils-Petter Rudqvist, Encouse B. Golden, et al.
Nature Medicine (2018) Vol. 24, Iss. 12, pp. 1845-1851
Open Access | Times Cited: 756
Harnessing innate immunity in cancer therapy
Olivier Demaria, Stéphanie Cornen, Marc Daëron, et al.
Nature (2019) Vol. 574, Iss. 7776, pp. 45-56
Closed Access | Times Cited: 751
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
Bertrand Allard, Maria Serena Longhi, Simon C. Robson, et al.
Immunological Reviews (2017) Vol. 276, Iss. 1, pp. 121-144
Open Access | Times Cited: 750
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Kevin C. Conlon, Enrico Lugli, Hugh C. Welles, et al.
Journal of Clinical Oncology (2014) Vol. 33, Iss. 1, pp. 74-82
Open Access | Times Cited: 628
Role of IL-2 in cancer immunotherapy
Tao Jiang, Caicun Zhou, Shengxiang Ren
OncoImmunology (2016) Vol. 5, Iss. 6, pp. e1163462-e1163462
Open Access | Times Cited: 465
Classification of current anticancer immunotherapies
Lorenzo Galluzzi, Erika Vacchelli, José Manuel Bravo‐San Pedro, et al.
Oncotarget (2014) Vol. 5, Iss. 24, pp. 12472-12508
Open Access | Times Cited: 440
Interleukin-33 and Interferon-γ Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation
Ari B. Molofsky, Frédéric Van Gool, Hong-Erh Liang, et al.
Immunity (2015) Vol. 43, Iss. 1, pp. 161-174
Open Access | Times Cited: 382
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Selena Viganó, Dimitrios Alatzoglou, Melita Irving, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 350
Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
Daniela S. Thommen, Jens Schreiner, Philipp Müller, et al.
Cancer Immunology Research (2015) Vol. 3, Iss. 12, pp. 1344-1355
Open Access | Times Cited: 348
CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer
Chunyan Gu‐Trantien, Edoardo Migliori, Laurence Buisseret, et al.
JCI Insight (2017) Vol. 2, Iss. 11
Open Access | Times Cited: 307
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Yan Tie, Fan Tang, Yuquan Wei, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 294
Emerging targets in cancer immunotherapy
Samantha Burugu, Amanda R. Dancsok, Torsten O. Nielsen
Seminars in Cancer Biology (2017) Vol. 52, pp. 39-52
Closed Access | Times Cited: 290
Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
Arabella Young, Deepak Mittal, John Stagg, et al.
Cancer Discovery (2014) Vol. 4, Iss. 8, pp. 879-888
Closed Access | Times Cited: 281
Immunosuppressive activities of adenosine in cancer
Bertrand Allard, Paul A. Beavis, Phillip K. Darcy, et al.
Current Opinion in Pharmacology (2016) Vol. 29, pp. 7-16
Closed Access | Times Cited: 250
The IL-2 cytokine family in cancer immunotherapy
Geok Choo Sim, Laszlo Radvanyi
Cytokine & Growth Factor Reviews (2014) Vol. 25, Iss. 4, pp. 377-390
Closed Access | Times Cited: 247
Tumor-related interleukins: old validated targets for new anti-cancer drug development
Sarra Setrerrahmane, Hanmei Xu
Molecular Cancer (2017) Vol. 16, Iss. 1
Open Access | Times Cited: 213
Pathways and therapeutic targets in melanoma
Emma Shtivelman, Michael A. Davies, Patrick Hwu, et al.
Oncotarget (2014) Vol. 5, Iss. 7, pp. 1701-1752
Open Access | Times Cited: 205
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
Salah-Eddine Bentebibel, Michael E. Hurwitz, Chantale Bernatchez, et al.
Cancer Discovery (2019) Vol. 9, Iss. 6, pp. 711-721
Open Access | Times Cited: 205
Regulatory T‐cell homeostasis: steady‐state maintenance and modulation during inflammation
Kate S. Smigiel, Shivani Srivastava, J. Michael Stolley, et al.
Immunological Reviews (2014) Vol. 259, Iss. 1, pp. 40-59
Open Access | Times Cited: 202
Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
Peter R. Rhode, Jack O. Egan, Wenxin Xu, et al.
Cancer Immunology Research (2015) Vol. 4, Iss. 1, pp. 49-60
Open Access | Times Cited: 201
A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control
Zhichen Sun, Zhenhua Ren, Kaiting Yang, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 173
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
Darci J. Phillips, Magdalena Matusiak, Belén Rivero‐Gutiérrez, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 157
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
Meenu Sharma, Hiep Khong, Faisal Fa’ak, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 148
Page 1 - Next Page

Scroll to top